FDA Orphan Drug Designated Immunitor V5 Development to be Accelerated
Key Capital Corporation (OTCMKTS:KCPC)
The sooner that we can achieve FDA approvals, the quicker we will be able to offer the many patients that currently have little to no hope the opportunity of possible positive disease response.”
— Peter Boonen, Chairman
NEW YORK, NY, USA, December 1, 2020 /EINPresswire.com/ — KEY CAPITAL CORPORATION (OTC Pink: KCPC) advises that in association with Immunitor Inc, the Company will seek to fast-track further clinical studies and regulatory approval of the FDA Orphan Drug Designated Immunitor V5 as a development priority.
Immunitor V5 has demonstrated unparalleled success in all clinical studies to date for the treatment of liver cancer, which is predominantly hepatocellular carcinoma (HCC). Immunitor studies report that patients taking just one oral Immunitor V5 immunotherapeutic vaccine tablet daily exhibited an industry unprecedented 12-month response and survival rate in 90% of cases. This dramatically exceeds the less than 10% average survival of HCC patients on conventional anticancer drugs.
Current Liver Cancer Situation and Options:
There is urgent need for an effective liver cancer treatment, as its incidence is increasing affecting over 800,000 people annually with a high mortality rate of about 700,000 per year, and treatment options being prohibitively expensive. In most patients, by the time HCC is diagnosed, surgical intervention or liver transplants are often not feasible, and conventional systemic chemotherapies have poor response success and are quite systemically toxic.
None of the currently approved or experimental HCC drugs are free from adverse side effects, nor have they secured significant success in treatment or shrinking tumors. Keytruda for example, aside from its high cost, only has a 10% positive response rate in 12-month HCC treatments.
Immunitor Breakthrough HCC Treatment
As reported in the February 2017 peer-reviewed open access Journal of Hepatocellular Carcinoma, in a recent c; over 90% of patients were responsive to V5 treatment and alive after a median 12 months of follow up – by comparison only about 10% are responsive after one year of treatment with Nexavar.
In an ongoing V5 study (See: ClinicalTrials.gov Identifier: NCT02232490), the high response rates and unprecedented safety experienced in previous V5 studies are being confirmed, as are clinical benefits, namely, improved liver function and tumor marker alphafetoprotein (AFP) decrease. AFP decrease correlates to tumor regression and where levels returned to normal, tumors disappeared. As indicative of the breakthrough potential of V5, all enrolled HCC patients were under palliative care, pronounced incurable, without available treatment options, and/or in terminal disease stage, having a variety of symptoms related to decompensated cirrhosis including ascites, edema, variceal bleeding, portal thrombi, and hepatic encephalopathy. (See: Hepatoma Research, Jan 2020)
Notably, the patented V5 harnesses the immune system by leveraging V5 immunotherapy to elicit a powerful immune response that combats cancer through natural process. V5 does not contain chemicals or live virus, nor any synthetic, engineered, or structured monoclonal antibodies, cytokines, or immune checkpoint inhibitors. V5 is not toxic, has no side effects, and does not cause any cytotoxicity, mutagenicity, teratogenicity, or genotoxicity. In fact, alongside demonstrating positive specific response to HCC, Immunitor V5 appears to also offer added broad-spectrum immunity benefits; however, this aspect needs to be further investigated.
Summary:
Despite the extraordinary and unprecedented success of the V5 liver cancer clinical studies to date, further and more comprehensive studies compliant with US FDA standards are now needed to confirm the Immunitor V5 study results and to progress to formal product approvals.
Company Chairman, Peter Boonen stated, “Immunitor has proven V5 safety, efficacy, and science, and also overcome the challenge of achieving immunotherapeutic benefits directly through the mucosa/microbiome, our primary defense against all disease and infection. I have personally seen extraordinary V5 success in terminal and non-treatable cancer cases that are now in full remission. The sooner that we can achieve FDA approvals, the quicker we will be able to offer patients in the broader market that currently have little to no hope the opportunity of possible positive disease response.”
Finally, the financial impact of the potential breakthrough Immunitor V5 immunotherapy oral pill vaccine offers vastly improved dynamics for all treatment stakeholders: the patient, family, carers, employers, insurers, hospitals, and government healthcare and military agencies. With the costs of Immunitor V5 immunotherapy for HCC at around 10% of other immunotherapies and Immunitor V5 treatment having no side effects or requiring hospitalization or complex treatment, the financial burden of HCC can be substantially eased. For example, the USA annual costs for military veterans HCC care, estimated at US$7.2 billion in 2016, could be dramatically reduced.
About Key Capital Corporation: The Company’s immediate objective is the further development of the oral pill immunotherapeutics opportunity through its Key Biotec and Immunitor partnering, particularly on advancing the Orphan Drug Designated V5 cancer candidate, along with early focus on disease conditions with unmet needs.
For further information see: https://keybiotec.com and https://keycapitalcorp.com
For all inquiries please contact: Key Capital at +1 (646) 401-0177, or Peter Boonen, Chairman, at [email protected]
References:
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=457714
https://www.keytruda.com/advanced-hepatocellular-liver-cancer/previously-treated-clinical-trials/
https://pubmed.ncbi.nlm.nih.gov/28443252/
https://hrjournal.net/article/view/3315
https://clinicaltrials.gov/ct2/show/NCT02232490?term=immunitor&draw=1&rank=3
https://www.natap.org/2017/HCV/122817_02.htm
Disclaimer: Statements made in this press release that express the Company or management’s intentions, plans, beliefs, expectations, or predictions of future events, are forward-looking statements. The words “believe,” “expect,” “intend,” “estimate,” “anticipate,” “will” and similar expressions are intended to further identify such forward-looking statements, although not all forward-looking statements contain these identifying words. Those statements are based on many assumptions and are subject to many known and unknown risks, uncertainties and other factors that could cause the Company’s actual activities, results or performance to differ materially from those anticipated or projected in such forward-looking statements. The Company cannot guarantee future financial results, levels of activity, performance or achievements and investors should not place undue reliance on the Company’s forward-looking statements.
Peter Boonen
Key Capital Corporation
+1 6464010177
Source: todayinscience.com
website is very good and informative
i really exicited about stem cells, can i discussion about it in email or telegram, i hope we can make a deal in the future
Just wish to say your article is as surprising The clearness in your post is just cool and i could assume youre an expert on this subject Fine with your permission allow me to grab your RSS feed to keep updated with forthcoming post Thanks a million and please keep up the enjoyable work
Just wish to say your article is as surprising The clearness in your post is just cool and i could assume youre an expert on this subject Fine with your permission allow me to grab your RSS feed to keep updated with forthcoming post Thanks a million and please keep up the enjoyable work
Hello my loved one I want to say that this post is amazing great written and include almost all significant infos I would like to look extra posts like this
Excellent blog here Also your website loads up very fast What web host are you using Can I get your affiliate link to your host I wish my web site loaded up as quickly as yours lol
您的网站设计非常精美，用户体验也非常出色，给人留下了深刻的印象！每一个细节都体现了专业和用心，真是让人赞叹不已。
can i get another review about stem cells?
We really interest about this stem cells.
I hope admin can read my email
The enthusiasm I have for your work matches your own. Your visual presentation is refined, and the content you’ve authored is of a high caliber. Nevertheless, you appear to be uneasy about the possibility of delivering something that may cause unease. I agree that you’ll be able to address this concern promptly.
What i dont understood is in reality how youre now not really a lot more smartlyfavored than you might be now Youre very intelligent You understand therefore significantly in terms of this topic produced me personally believe it from a lot of numerous angles Its like women and men are not interested except it is one thing to accomplish with Woman gaga Your own stuffs outstanding Always care for it up
Attractive section of content I just stumbled upon your blog and in accession capital to assert that I get actually enjoyed account your blog posts Anyway I will be subscribing to your augment and even I achievement you access consistently fast
Hi can you make a china version of this website? In China need china version
I believe many professor here will interest
I do agree with all the ideas you have introduced on your post They are very convincing and will definitely work Still the posts are very short for newbies May just you please prolong them a little from subsequent time Thank you for the post
Somebody essentially help to make significantly articles Id state This is the first time I frequented your web page and up to now I surprised with the research you made to make this actual post incredible Fantastic job
Salam Dari Indonesia, Untuk whatsapp tidak bisa dichat kenapa? Saya ingin diskusi Dan membeli
Seharusnya yang begini disupport pemerintah Indonesia
La interfaz de usuario es extremadamente amigable. Los colores, las fuentes y la disposición de los elementos se combinan para proporcionar una experiencia visual agradable y coherente
Interested but Waiting For More Reviews
“I was really impressed with the product offerings and the detailed information on the website. However, the prices are currently a bit out of my budget. I’ll be keeping an eye on any future sales or promotions
After reviewing the website, I found the products to be quite interesting and potentially very effective. However, I’m hesitant to purchase right now because I haven’t seen enough customer reviews about their long-term effectiveness and durability
Thankyou google, you Bring me here
Thats plenty future technology and this is vert good
Infinity Stem Cells provides a deep dive into the therapeutic applications of stem cells, particularly in regenerative medicine.
The articles are well-researched and cover a wide range of topics, from the basics of stem cell biology to the latest breakthroughs in research and therapy. I appreciated the clarity of the explanations; they made complex concepts accessible and engaging.
I recently visited here, got it from ads, and I was thoroughly impressed with the wealth of information available. The website offers a user-friendly layout that makes navigation a breeze, even for someone new to the topic of stem cells.
The information on this stem cell website is comprehensive and well-researched. It helped me understand the potential of stem cell therapy for various conditions. Highly recommend!”